A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

NCT06790121 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis Atopic

Interventions

DRUG: Lunsekimig
DRUG: Placebo

Sponsor

Sanofi